2025 Oncology Institute
April 19, 2025 | 4:34 PM EST
- Home
- Clinical Resources Search
- PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 2
Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 2
Download PQI pdf 1.31MB
Last Updated: December 1, 2021
By: Utah Cancer Specialists, UT | Astera Cancer Care, NJ
About this PQI in Action
In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Cabazitaxel ( JEVTANA®) For Patients with Metastatic Castration-Resistant Prostate Cancer PQI and explores how the Medically Integrated Teams at Utah Cancer Specialists (UCS) and Astera Cancer Care incorporate PQIs as part of their daily workflow. This article will discuss how utilizing the Cabazitaxel ( JEVTANA®) For Patients with Metastatic Castration-Resistant Prostate Cancer PQI elevates patient care.
More About This PQI in Action
Find a PQIPQI in Action
PQI in Action: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration Resistant Prostate Cancer – 1
Last Updated: April 1, 2021
PQI
PQI: Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer
Last Updated: February 22, 2024